Back to Journals » Cancer Management and Research » Volume 12

Efficacy and Safety of Anlotinib in Advanced Non-Small Cell Lung Cancer: A Real-World Study

Authors Zhang K, Ma X, Gao H, Wang H, Qin H, Yang S, Liu X

Received 16 January 2020

Accepted for publication 22 April 2020

Published 13 May 2020 Volume 2020:12 Pages 3409—3417

DOI https://doi.org/10.2147/CMAR.S246000

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Professor Lu-Zhe Sun


Kun Zhang,1,2 Xiya Ma,2 Hongjun Gao,2 Hong Wang,2 Haifeng Qin,2 Shaoxing Yang,2 Xiaoqing Liu2

1Academy of Military Medical Science, Beijing 100089, People’s Republic of China; 2Department of Lung Oncology, The Fifth Medical Center of Chinese PLA General Hospital, Beijing 100071, People’s Republic of China

Correspondence: Xiaoqing Liu
Department of Lung Oncology, The Fifth Medical Center of Chinese PLA General Hospital, No. 8 East Street, Fengtai District, Beijing 100071, People’s Republic of China
Tel + 8610-66947963
Fax + 8610-51128605
Email liuxiaoqing0612@163.com

Purpose: The ALTER0303 trial showed that anlotinib, a novel antiangiogenic tyrosine kinase inhibitor, administered as third-line or further treatment prolonged progression-free survival (PFS) and overall survival (OS) in patients with advanced non-small cell lung cancer (NSCLC). This retrospective study investigated the efficacy and safety of anlotinib in real-world settings.
Patients and Methods: Medical records of patients with advanced NSCLC receiving anlotinib as third-line or further treatment were collected, and survival curves were derived using the Kaplan–Meier method. Univariate analysis was performed by log-rank testing. Cox regression analysis was used to evaluate the significance of factors obtained from the univariate analysis.
Results: Fifty-two patients with advanced NSCLC were included. The objective response rate was 16%, and the disease control rate was 80%. The median PFS was 4.5 months (95% confidence interval [CI]: 3.6– 5.4), and the median OS was 9 months (95% CI: 6.5– 11.5). Univariate analysis revealed that the group of patients with longer PFS and OS included Eastern Cooperative Oncology Group performance status (ECOG PS) ≤ 1, ≤ 2 distant metastases, no liver metastases, ≤ 3 previous treatment lines, and ≤ 2 previous chemotherapy lines. Cox regression analysis demonstrated that only patients with ECOG PS ≤ 1 or no liver metastases had longer PFS and OS. Grade 3 treatment-related adverse events were reported in 14% of the patients, but no life-threatening adverse events were reported.
Conclusion: Anlotinib was well tolerated and effective in patients with advanced NSCLC in real-world conditions. Patients with ECOG PS ≤ 1 or no liver metastases have longer PFS and OS.

Keywords: anlotinib, non-small cell lung cancer, antiangiogenesis, third-line or further treatment, real-world study

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]